BioClinica, Inc. Merger Litigation (Nasdaq: BIOC)
Law Office of Brodsky & Smith, LLC Announces Investigation of BioClinica, Inc.
BALA CYNWYD, January 30, 2013/PR Newswire/ –Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of BioClinica, Inc. (“BioClinica” or the “Company”) (Nasdaq- BIOC-News) relating to the acquisition by a holding company controlled by JLL Partners, Inc. (“JLL”).
Under the terms of the transaction, BioClinica shareholders will receive only $7.25 in cash for each share of BioClinica stock they own. The investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of BioClinica for not acting in the Company’s shareholders' best interests in connection with sale process to JLL. The transaction may undervalue the Company as an analyst has set a $9.00 per share price target on BioClinica stock.
If you own shares of BioClinica stock and wish to discuss the legal ramifications of the proposed transaction, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 602, Bala Cynwyd, PA 19004, by e-mail at email@example.com by calling toll free 877-LEGAL-90.
To Join the BioClinica, Inc. Litigation
Fill out this form
The complaint is unavailable at this time